Athenex Inc

Athenex — Technical Presentation (December 2019)

19 slides from Athenex's technical presentation, Dec 13, 2019

  1. Slide 1: Oral paclitaxel with encequidar (OPE): Phase III study in metastatic breast cancer

    Oral paclitaxel with encequidar (OPE): The first orally administered paclitaxel shown to be superior to IV paclitaxel on confirmed response and survival with less neuropathy: A Phase III clinical study in metastatic breast cancer Umanzor G1, Rugo HS2, Barrios FJ3, Vasallo RH4, Chivalan MA5, Bejarano

  2. Slide 2: Author disclosures

    Author disclosures Umanzor G Nothing to disclose Rugo HS Research support for clinical trials through the University of California San Francisco (UCSF) from: Eisai, Daiichi Sankyo, Genentech/Roche, Eli Lilly, MacroGenics, Merck, Novartis, OBI Pharma, Inc., Odonate, Pfizer, and Plexxikon; received tr

  3. Slide 3: Metastatic Breast Cancer and Paclitaxel

    Metastatic Breast Cancer and Paclitaxel Taxanes remain a foundation of breast cancer treatment1 IV Paclitaxel FDA-approved schedule for mBC2,3: 175 mg/m2 Q 3 weeks IV Paclitaxel US clinical practice3: 80 mg/m2 IV Q week (varies by site, Q 3-4 weeks) Benefits of an oral mode of administration include

  4. Slide 4: Dose Justification for OPE

    Dose Justification for OPE aMedian=2 lines of therapy; bPatient had a new lesion; C30% is clinically meaningful. AUC, area under the curve; mBC, metastatic breast cancer; PK, pharmacokinetic; QD, once daily. 1. Jackson C, et al. ESMO, Barcelona, Spain, 2019, 477-P; 2. Dai MS, et al. ASCO, Chicago, I

  5. Slide 5: Study Design

    *360 Evaluable Patients OPE (n=240) IV Paclitaxel (n=120) 80% power, 15% difference in confirmed RR (P=0.045) 1-3 4-6 7-9 10-12 13-15 16-18 19a 20,21 22 23,24 25+ Study Design aIf first response at week 19, then week 22 scan obtained; bDefined as last patient, last scan; bComputer-generated algorith

  6. Slide 6: Patient Selection and Analysis Populations

    Patient Selection and Analysis Populations Prespecified mITT Population (N=360) Baseline evaluable scan: patients with metastatic RECIST lesion on central review All patients who received at least 7 doses of OPE or one dose of IV Paclitaxel OPE (n=235); IV Paclitaxel (n=125) All patients who were ra

  7. Slide 7: Paclitaxel Dosing and Administration

    Paclitaxel Dosing and Administration Week 1 Week 2 Week 3 1 Cycle Oral Paclitaxel and Encequidar (OPE) Encequidar: 15 mg tablet Oral paclitaxel: each capsule contains 30 mg solubilized paclitaxela Intravenous Paclitaxel Administered as 175 mg/m2 over a 3-hour infusion every 3 weeks (1 cycle) aPaclit

  8. Slide 8: Baseline Patient Characteristics and Demographics

    Baseline Patient Characteristics and Demographics: Prespecified mITT Population (N=360) Patient Characteristics OPE (n=235) IV Paclitaxel (n=125) Age, years, mean (range) 57.2 (30-90) 55.7 (32-85) Age category ≥65, % 26 25 Race/ethnicity, % Hispanic/Latino 88 90 Othera 12 10 ECOG status, % PS 0 59 5

  9. Slide 9: Prior Therapies and Metastatic Disease in Prespecified mITT Population

    Prior Therapies and Metastatic Disease in Prespecified mITT Population Prior Therapy Exposure OPE (n=235) IV Paclitaxel (n=125) Number of prior chemotherapies in metastatic setting, % Any 26 28 1 14 16 2 7 8 ≥3 4 6 Prior taxane exposure (any setting), % 29 30 Prior anthracycline exposure (any settin

  10. Slide 10: Primary Endpoint: OPE Increased Confirmed RR Compared to IV Paclitaxel

    Primary Endpoint in Prespecified mITT Population (Final Analysis): OPE Increased Confirmed RR Compared to IV Paclitaxel Tumor Evaluations OPE IV Paclitaxel Stable disease, % 23.8 39.2 Progressive disease, % 16.2 21.6 aITT analysis of the primary endpoint is also significant. Confirmed Response Ratea

  11. Slide 11: Subgroup Analysis: Tumor Response by Central Review

    Subgroup Analysis in Prespecified mITT Population: Tumor Response by Central Review Response Rate Differencea aResponse rate difference is calculated as the rate from the OPE group minus the rate from the IV Paclitaxel group. IV Paclitaxel better OPE better OPE (n=235) IV Paclitaxel (n=125) -0.5 -0.

  12. Slide 12: Duration of Response in Prespecified mITT Population

    y 5 9 13 25 21 17 29 33 37 41 45 49 53 57 61 65 69 73 77 81 85 89 93 Ongoing Duration of Response in Prespecified mITT Population: Trend for OPE in Patients With Confirmed Tumor Response Duration of Response, days >100 >200 >300 Duration of response, % 74.7 33.7 12.6 0 20 40 60 80 100 120 140 160 18

  13. Slide 13: Ongoing Analysis PFS in Prespecified mITT Population

    Ongoing Analysis PFS in Prespecified mITTa Population HR=0.760 (95% CI: 0.551,1.049) Cumulative Progression-Free Survival Months (Relative to Randomization) OPE IV Paclitaxel Numbers of Subjects at Risk OPE 235 219 208 174 154 130 119 87 84 55 49 27 23 20 15 13 12 6 6 4 3 2 1 1 1 0 IV Paclitaxel 125

  14. Slide 14: Ongoing Analysis OS in Prespecified mITT Population

    Ongoing Analysis OS in Prespecified mITT Population Log-Rank Test P=0.0353 Cumulative Overall Survival OPE IV Paclitaxel Months (Relative to Randomization) Numbers of Subjects at Risk OPE 235 229 218 190 162 130 107 84 66 48 42 31 27 23 18 10 7 4 2 0 IV Paclitaxel 125 121 114 99 85 65 47 40 33 24 17

  15. Slide 15: TEAEs (CTCAE Grade ≥2) With ≥10% Overall Incidence Rate

    28.8 28.8 14.8 2.3 12.5 10.6 2.3 8.3 1.5 6.1 48.1 48.1 33.3 3.7 29.6 7.4 3.0 4.4 31.1 14.8 16.3 38.3 14.8 15.2 8.3 19.7 2.3 17.4 18.9 3.4 15.5 33.3 8.9 19.3 5.2 10.4 10.4 11.9 11.9 24.2 4.9 18.9 23.1 3.8 19.3 17.0 4.9 12.1 13.6 2.3 11.4 8.1 1.5 6.7 5.2 4.4 4.4 3.7 4.4 1.5 3.0 TEAEs (CTCAE Grade ≥2)

  16. Slide 16: Treatment-emergent Adverse Events of Interest

    Estimate Neuropathyb with CTCAE grade ≥2 -0.235 Alopecia with CTCAE grade 2 -0.194 Neutropenia with CTCAE grade ≥3 0.018 Diarrhea with CTCAE grade ≥3 0.038 Vomiting or nausea with CTCAE grade ≥3c 0.061 0 10 20 30 40 50 60 % Population Treatment-emergent Adverse Events of Interest: Safety Population

  17. Slide 17: Neuropathy TEAEs (CTCAE Grade ≥2)

    Neuropathya TEAEs (CTCAE Grade ≥2): Safety Population (N=399) aNeuropathy TEAEs include burning sensation, dysesthesia, hypoesthesia, hyporeflexia, neuralgia, neuropathy peripheral, neurotoxicity, paresthesia, peripheral motor neuropathy, peripheral sensory neuropathy, and polyneuropathy. Numbers of

  18. Slide 18: Conclusions

    Conclusions Oral paclitaxel and encequidar is the first oral taxane in a Phase III trial to demonstrate a significant improvement in confirmed overall response rate compared to IV paclitaxel In the modified intent-to-treat population, centrally confirmed ORR increased from 25.6% with IV paclitaxel t

  19. Slide 19: Acknowledgments: Patients, Families, and Investigators

    Acknowledgments: Patients, Families, and Investigators Guatamala Mario Fredy Sandoval Castañeda Clinica Dr. Mario Freddy Sandoval Francisco Javier Barrios Schaeffer American Cancer Center Julio Roberto Ramírez Velasquez Centro Regional de Sub-Especialidades Médicas S.A. (CRESEM S.A.) Carmen Silvana

Athenex — Technical Presentation (December 2019) on 6ix